Stock MIRM MIRUM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
23.81 USD +1.02% Intraday chart for Mirum Pharmaceuticals, Inc. -3.13% -19.34%
Apr. 17 Stifel Initiates Mirum Pharmaceuticals With Buy Rating, $48 Price Target MT
Apr. 02 Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome CI

Business Summary

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Number of employees: 264

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Therapies
100.0 %
77 100.0 % 186 100.0 % +141.85%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
82.0 %
77 100.0 % 147 82.0 % +90.36%
Rest of World
18.0 %
-- 32 18.0 % -

Managers

Managers TitleAgeSince
Christopher Peetz FOU
 Founder 45 18-05-06
Michael Grey FOU
 Founder 71 18-05-06
Peter Radovich PSD
 President 46 20-04-27
Eric Bjerkholt DFI
 Director of Finance/CFO 64 23-09-10
Pamela Vig CTO
 Chief Tech/Sci/R&D Officer 53 18-11-30
Joanne Quan CTO
 Chief Tech/Sci/R&D Officer 60 Jan. 15
Paul K. Ross CMP
 Compliance Officer - 20-03-31
Andrew McKibben IRC
 Investor Relations Contact - -
Erin Campany HRO
 Human Resources Officer 57 21-12-31
Lara Krupka-Longpre PRN
 Corporate Officer/Principal 54 18-11-30

Members of the board

Members of the board TitleAgeSince
Timothy Walbert BRD
 Director/Board Member 57 23-04-04
Michael Grey FOU
 Founder 71 18-05-06
Patrick Heron BRD
 Director/Board Member 53 18-11-06
Laurent Fischer BRD
 Director/Board Member 60 19-05-31
Laura Brege BRD
 Director/Board Member 66 19-07-16
Sona Saira Ramasastry BRD
 Director/Board Member 48 22-06-01
Christopher Peetz FOU
 Founder 45 18-05-06
Lon Cardon BRD
 Director/Board Member - 22-12-18
William Fairey BRD
 Director/Board Member 59 21-08-18

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 47,003,329 45,060,786 ( 95.87 %) 0 95.87 %

Shareholders

NameEquities%Valuation
Frazier Life Sciences Management LP
13.93 %
6,495,392 13.93 % 163 M $
BVF, Inc.
9.375 %
4,370,024 9.375 % 110 M $
Eventide Asset Management LLC
5.714 %
2,663,649 5.714 % 67 M $
Vanguard Fiduciary Trust Co.
5.312 %
2,476,244 5.312 % 62 M $
BlackRock Advisors LLC
5.040 %
2,349,532 5.040 % 59 M $
Janus Henderson Investors US LLC
4.425 %
2,062,551 4.425 % 52 M $
Cadian Capital Management LP
4.151 %
1,934,922 4.151 % 49 M $
Rock Springs Capital Management LP
3.972 %
1,851,464 3.972 % 47 M $
STATE STREET CORPORATION
3.722 %
1,734,775 3.722 % 44 M $
Novo Holdings A/S (Investment Company)
3.218 %
1,500,000 3.218 % 38 M $

Company contact information

Mirum Pharmaceuticals, Inc.

950 Tower Lane Suite 1050

94404, Foster City

+650 667 4085

http://www.mirumpharma.com
address Mirum Pharmaceuticals, Inc.(MIRM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for Mirum Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
23.81 USD
Average target price
48.91 USD
Spread / Average Target
+105.41%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MIRUM PHARMACEUTICALS, INC. Stock Mirum Pharmaceuticals, Inc.
-19.34% 1.11B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.42% 41.35B
LONZA GROUP AG Stock Lonza Group AG
+42.15% 40.38B
MODERNA, INC. Stock Moderna, Inc.
+1.97% 39.05B
CELLTRION, INC. Stock Celltrion, Inc.
-14.19% 26.67B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+1.82% 24.07B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.55% 18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-4.07% 11.68B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+21.36% 11.6B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.20% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MIRM Stock
  4. Company Mirum Pharmaceuticals, Inc.